Journal article

High reproducibility of histological diagnosis of human papillomavirus-related intraepithelial lesions of the anal canal

Jennifer M Roberts, Fengyi Jin, Julia K Thurloe, Clare Biro, Isobel M Poynten, Sepehr N Tabrizi, Christopher K Fairley, David J Templeton, Andrew D Carr, Suzanne M Garland, Richard J Hillman, Alyssa M Cornall, Andrew E Grulich, Annabelle Farnsworth

PATHOLOGY | ELSEVIER | Published : 2015


In a natural history study of anal human papillomavirus (HPV) infection and HPV-related lesions, we examined the reproducibility of histological high-grade squamous intraepithelial lesion (HSIL). Three expert anogenital pathologists share the reporting of histological specimens from the Study of the Prevention of Anal Cancer (SPANC), utilising Lower Anogenital Squamous Terminology (LAST) criteria. In total, 194 previously reported biopsies were randomly chosen within diagnostic strata [50 HSIL-anal intraepithelial neoplasia (AIN) 3; 45 HSIL-AIN 2; 49 'flat' low-grade squamous intraepithelial lesion (LSIL); 50 'exophytic' LSIL; and 50 negative for squamous intraepithelial lesion] and reviewed..

View full abstract


Awarded by NHMRC

Awarded by Cancer Council NSW Strategic Research Partnership Program

Awarded by National Health and Medical Research Council

Funding Acknowledgements

SMG has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has also received funding through her institution to conduct HPV vaccine studies for MSD and GSK. She is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. RJH has received payment for lectures from Gilead, CSL and Merck.ADC is on the boards of Gilead Sciences, MSD and ViiV Healthcare and has received consultancy fees, grants and payment for lectures from these entities.The remaining authors have no conflicts of interest to declare. The Study of the Prevention of Anal Cancer is funded by a NHMRC program grant (#568971) and a Cancer Council NSW Strategic Research Partnership Program grant (#13-11). Cytological testing materials are provided by Hologic (Australia) Pty Ltd. IMP (#1016307) and DJT (#1013353) are supported by Post-doctoral Training Fellowships from the National Health and Medical Research Council.